2026-07-082 min
Sermorelin: Human Trial Design and Evidence Boundaries
An evidence-led Sermorelin review focused on human trial design, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskClinical Trials
Structured reviews of registered and published human studies involving GH-axis peptides.
Open
2026-07-052 min
Ipamorelin: Small-Study Statistics and Evidence Boundaries
An evidence-led Ipamorelin review focused on small-study statistics, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review Desk2026-07-022 min
Ipamorelin: Human Trial Design and Evidence Boundaries
An evidence-led Ipamorelin review focused on human trial design, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-06-292 min
Modified GRF (1-29): Small-Study Statistics and Evidence Boundaries
An evidence-led Modified GRF (1-29) review focused on small-study statistics, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-06-262 min
Modified GRF (1-29): Human Trial Design and Evidence Boundaries
An evidence-led Modified GRF (1-29) review focused on human trial design, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-06-232 min
CJC-1295 DAC: Small-Study Statistics and Evidence Boundaries
An evidence-led CJC-1295 DAC review focused on small-study statistics, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial Team2026-06-202 min
CJC-1295 DAC: Human Trial Design and Evidence Boundaries
An evidence-led CJC-1295 DAC review focused on human trial design, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk